Teladoc's disappointing earnings are causing a knee-jerk sell-off across healthcare stocks as investors flee the sector. But Novo Nordisk and Eli Lilly operate in the booming weight-loss drug market, which is completely disconnected from telehealth strugg

Verdict: Wait — the dip-buying thesis is alive but the trigger hasn't fired and may be too strict to ever fire

The idea's core thesis — that a Teladoc-driven healthcare panic is mispricing GLP-1 leaders — has real fundamental legs for Eli Lilly, whose 44.7% revenue growth and 77.8% ROE place it in the top decile of healthcare peers. But the setup demands simultaneous RSI below 35, Stochastic %K below 30, and a support touch, and across 1,718 evaluated bars over two windows the rules have never triggered once. That makes this a disciplined watch-list exercise, not a live trade: the strategy is designed to catch exhaustion, and today neither ticker has washed out enough — NVO's Stochastic %K sits at 46.7 (16.7 points above the sub-30 gate) and LLY's at 37.9 (7.9 points away). The deeper problem is NVO itself: 6.4% revenue growth, a current ratio of 0.80, and a 74.6% historical max drawdown undercut the "booming demand" framing and make it the basket's structural drag. No robust parameter setup was established through sensitivity testing, so the original strict thresholds stand. **Conviction Breakdown** | Dimension | Score | Rationale | |---|---|---| | Thesis Support | 55 | The telehealth-contagion disconnect is plausible for LLY (44.7% revenue growth, 77.8% ROE) but weak for NVO (6.4% growth, only 35th percentile among peers). | | Trade Readiness | 25 | Zero triggers across 1,718 bars; Stochastic %K is 7.9–16.7 points from the sub-30 gate on both tickers, and no relaxed setup was established. | | Risk Quality | 55 | The 2.5% stop and 2:1 reward-to-risk are disciplined, but NVO's 49.7% annualized volatility and 74.6% max drawdown make the basket vulnerable to gap-throughs. | | Trigger Proximity | 30 | NVO has RSI (31.4) and support ($47.00) in place but needs a 16.7-point Stochastic drop; LLY needs both a deeper RSI breach and a $97 pullback to $1,052 support. | | Fundamentals Trend | 60 | LLY's growth and margins are accelerating; NVO's margins are compressing (gross margin down to 81.0% from 84.7%) and its current ratio of 0.80 signals liquidity pressure. |

Trade now

Neither ticker has triggered an entry yet, so the instruction today is to wait — but the waiting is active. The strategy requires four conditions to fire simultaneously: RSI (14) below 35, Stochastic %K crossing above %D while %K itself is still below 30, price touching the nearest support level, and then closing above the prior close. For Eli Lilly, RSI sits at 35.0 — effectively at the threshold — but Stochastic %K is at 37.9, still well above the sub-30 zone needed for the crossover condition. Price at $1,148.8 is also sitting right at nearest resistance ($1,149.1), not the $1,052.2 support the entry requires. Novo Nordisk is further along on the oversold axis: RSI is already at 31.4 (below the 35 gate) and price at $47.08 is essentially on top of its $47.00 nearest support. However, Stochastic %K at 46.7 is nowhere near the sub-30 band the strategy demands before it will recognize a momentum turn. The invalidation framework is tight by design. Once entered, a fixed stop caps losses at roughly 2.5% and take-profit targets approximately 4.9%, giving an effective reward-to-risk near 2:1. The strategy also layers in a Fibonacci 78.6% retracement stop-loss and a new-low invalidation. Because no robust parameter setup was established through sensitivity testing (the evaluation exceeded its time budget), there is no adjusted or relaxed threshold set to fall back on — the original, stricter rules stand. "Wait" means something concrete here: set alerts on Stochastic %K dropping below 30 for both tickers, since that is the condition furthest from being met on NVO (16.7 points away) and significantly off on LLY (7.9 points away). For LLY, also watch for a roughly $97 pullback from current price to the $1,052 support level. NVO is the closer candidate — RSI and support are already in place — but it needs a deeper Stochastic wash-out before the crossover signal can even be evaluated.

Why the GLP-1 Demand Story Still Has Teeth

The central thesis — that a telehealth-driven sell-off is dragging down fundamentally unrelated weight-loss stocks — rests on a…

Scores

• Conviction score breakdown: 45
• Thesis support: 55
• Trade readiness: 25
• Risk quality: 55
• Trigger proximity: 30
• Fundamentals trend: 60

Watch items

• LLY — RSI (14)
• LLY — Stochastic (14) %K
• LLY — Price vs nearest support
• NVO — RSI (14)
• NVO — Stochastic (14) %K
• NVO — Price vs nearest support
• NVO — Annualized return (730-day)
• LLY — RSI (14) below 35
• LLY — Stochastic (14) crossed above Stochastic (14)
• LLY — Stochastic (14) below 30
• LLY — Price above Price